A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Up to 40% of patients with PBC have an inadequate response to standard treatment with
Ursodeoxycholic Acid (UDCA), those patients represent the group in need for additional
therapies, having increased risk of disease progression and decreased survival free of liver
transplantation.
The main objective of the study is to evaluate safety and efficacy of bezafibrate plus
ursodesoxicolic acid in patients with PBC and inadequate response to UDCA.